AHD-RESEARCH-002 — Synthesis of NEXUS Swarm Findings v1.0
Avina Home Detox LLC Status: LANDED (5 of 5 seats returned) Date: 24/04/2026 Author: NEXUS Council swarm + main-thread synthesis Token cost: ~$3-5 USD across all 5 seats (vs ~$50-200 inline Opus)
Executive Summary — What Changed
The five research seats returned an unusually consequential set of findings. Three of them require immediate revision of foundational documents. The other two confirm the strategic position. This synthesis captures the critical pivots before they propagate through downstream artefacts.
The headline: the white-space thesis (in-residence medical detox + integrated IV under MD on-site for family-office buyers) is confirmed with no direct US competitor occupying the position. However, the cost basis, the legal structure, and the marketing claims require material revision before stand-up. The capital plan needs a $15-30K addition for HHA licensure. The 1099 nurse cost model is likely illegal under California AB5 and must shift to employee or true PC-based contractor classification. NAD marketing claims must be carefully scoped to avoid regulatory exposure.
SEAT 01 — NAD IV Clinical Evidence (LANDED)
Bottom line
The clinical evidence base for IV NAD+ in alcohol or opioid withdrawal is thin and observational only. There is no published placebo-controlled randomised controlled trial in addiction populations as of April 2026. The Mestayer (n=26 retrospective, conference-only) and Blum (n=50 open-label) are the available human pilot data, both with industry conflicts. Mechanistic rationale for mitochondrial cofactor repletion is sound. NAD must be presented as an emerging adjunct, not as evidence-based treatment.
Defensible claims AHD can make
- “IV NAD+ therapy provides mitochondrial cofactor repletion during a period when chronic substance use has depleted cellular energy substrates.”
- “Our protocols include IV thiamine, which is clinically established to prevent Wernicke encephalopathy in alcohol-dependent patients.”
- “Glutathione infusion supports hepatic antioxidant capacity during alcohol detoxification.”
- “Pilot clinical data suggest IV NAD+ protocols may reduce withdrawal-associated anxiety and craving scores; larger controlled trials are in progress.”
Claims to AVOID
- “Evidence-based NAD+ treatment” or “clinically proven”
- “NAD+ eliminates withdrawal symptoms”
- “NAD+ rewires the brain’s reward pathways”
- “NAD+ detoxifies the body”
- Citing Daniel Sumrok as an NAD+ advocate (he isn’t)
- “Endorsed by addiction medicine specialists” (ASAM/ABAM have not endorsed)
Action
- Update AHD-IV-LIBRARY to v0.2 with evidence grades by protocol (HIGH for thiamine, MEDIUM for hydration/Mg/glutathione hepatic, LOW for NAD efficacy, MEDIUM for NAD safety + mechanism)
- Update marketing copy on the marketing site: re-write any NAD-adjacent claims through this lens
- Medical Director Agreement language: NAD documented as “emerging/adjunct therapy” with prescribing rationale per case
SEAT 02 — Concierge IV Competitive Landscape (LANDED)
Bottom line
The white space is confirmed. No US operator currently sits at the intersection of: (a) in-principal-residence, (b) full medical detox capability with addiction-medicine MD on-site, (c) NAD/IV as named integrated component, (d) family-office buyer language. The closest competitors (Kinkaid Private Care, Detox Concierge, MD Home Detox) are either RN-led with remote MD oversight, lack named NAD integration, or don’t market to family offices.
Tier landscape
| Tier | Players | Pricing | Why not AHD’s territory |
|---|---|---|---|
| Mid-tier mobile (RN, remote MD) | Drip Hydration, Reset IV, IV Doc, ConciergeMD LA | $500-$999/NAD session | No detox capability; wellness positioning |
| UHNW concierge urgent care | Sollis Health (membership), NextHealth (clinic) | $4-12K/yr membership | Clinic-based or urgent care, not in-residence detox |
| Closest US competitors | Kinkaid Private Care, Detox Concierge | Opaque | Remote MD; CA-only; no FO marketing |
| Residential ultra-luxury | Paracelsus ($107-136K/wk), Kusnacht ($133K/wk) | Published | Switzerland, requires travel, residential not in-residence |
NAD pricing benchmarks (verified)
- Mid-tier mobile RN: $500-800 / 500mg session
- Premium mobile MD/NP: $999 / 500mg-with-glutathione session
- High-end clinic: $1,495 / 1,000mg session
- Residential bundled: not itemised
- AHD position: per-engagement retainer, NOT per-session
Three positioning recommendations (verified against competitor claims)
- “No facility, no admission record” — claim no competitor can match
- Name the buyer as the family office — Sollis/NextHealth/ConciergeMD all market to the patient
- MD as credential signal, not IV menu — align with Paracelsus voice register
Action
- Update AHD-PRICING-ARCHITECTURE-v0.1 to v0.2 — confirm three-tier model holds against benchmarks (it does)
- Update marketing site copy (avinahomedetox.com draft) with the three positioning recommendations
- Update Brand Direction with the white-space positioning explicit
SEAT 03 — Regulatory Map CA/NY/FL (LANDED) — CRITICAL
Bottom line
Three of the five regulatory landmines materially change the cost basis and structure of the business. Operating without them is unlawful. Mitigations are concrete but expensive in time and cost.
LANDMINE 1: HHA Licensure Required in All 3 States
- CA: Home Health Agency licensure under H&S §1726
- NY: LHCSA or CHHA under PHL Article 36
- FL: AHCA under Ch. 400, Part III
- Impact: Adds $15-30K + 60-120 days per state to stand-up
- Capital Plan delta: +$30K Y1 (move into existing $25K state-licensure line and add)
- Mitigation: Engage counsel on Day 1 to file all three concurrently; explore narrow exemption arguments (pure platform/coordination, MD-employee structure)
LANDMINE 2: 1099 RN Model is Likely Illegal in California (AB5 / Labor Code §2775)
- ABC test Prong B fails because RNs deliver the LLC’s core service
- Exposure: wage-and-hour claims, payroll tax, workers comp, PAGA penalties (multi-million dollar precedent)
- Impact: Cost model assumed 1099 RNs; must shift to employees OR engage RNs who operate their own PCs/LLCs with multi-client portfolios
- Capital Plan delta: Y1 cost basis shifts. Employed RN with benefits/payroll burden adds ~30-40% on top of base hourly. New blended cost = $110-130/hr deployed (vs $75-90 in current model)
- Mitigation: Either (a) classify CA RNs as W-2 employees and absorb the cost, or (b) use only RNs who can demonstrate AB 2257 business-to-business compliance with documented multi-client status
LANDMINE 3: Controlled Substance Chain of Custody
- 1099 RNs cannot lawfully transport Schedule III (Subutex) or Schedule IV (Ativan) under DEA security regulations (21 CFR Part 1301)
- A 1099 RN carrying medications house-to-house is in violation
- Mitigation: Entity-level DEA registration + RNs as employees acting under that registration; OR pharmacy-courier delivery model with same-day administration
LANDMINE 4: EKRA Exposure on Referral Compensation
- Federal criminal: $200K + 10 years per occurrence
- Any volume-correlated comp to clinicians, marketers, or referral partners is a violation
- Mitigation: Already addressed in Medical Director Agreement (all comp fixed, not per-referral). Validate with counsel before any new vendor/partner signed.
- State analog: Florida §817.505 patient brokering (felony) — lower proof threshold than EKRA, actively prosecuted
LANDMINE 5: Multi-State MD Licensure + DEA Registration
- Elizabeth (CA-licensed) cannot prescribe to NY/FL patients without state-specific licensure + DEA
- Impact: Y1 NY/FL launch is gated on Elizabeth obtaining licensure in each state
- Mitigation: Begin NY + FL applications Day 1 in parallel. FL is IMLC member (expedited pathway available). NY requires full process. Plan for 6-9 months for NY licensure.
Helpful Findings
- DEA telemedicine flexibilities extended through Dec 31, 2026 (audio-video for Ativan; audio-only for buprenorphine)
- Buprenorphine via audio-only telemedicine permanently authorised under Jan 2025 final rule
- This means once Elizabeth is licensed in each state, telemedicine prescribing for case continuity is operationally viable
Other Critical Findings
- CMIA stricter than HIPAA in CA: 30-day breach notification (vs 60), private right of action $1,000/violation, 14-point typeface authorisation
- Per-patient physician orders required in CA home-health context; standing orders alone are not sufficient
- OASAS (NY) and DCF (FL) may assert jurisdiction over physician-supervised home detox even without behavioural programming — get advance written guidance before launch in each
Action
- Update AHD-CAPITAL-PLAN-v0.1 to v0.2 — add HHA licensure cost; revise nurse cost basis from 1099 to employee equivalent
- Update AHD-REGULATORY-MAP-v0.1 to v0.2 — replace placeholder with the verified findings above
- Update AHD-90-DAY-SPRINT — add multi-state MD licensure and HHA filings to Day 1
- Brief Nelson Hardiman counsel: AB5 structure, HHA exemption analysis, DEA registration for entity, OASAS/DCF advance guidance requests
- Operating Manual §VII (Controlled Substance Handling) — revise to reflect chain-of-custody requirements
SEAT 04 — Combined Detox + IV Protocol (LANDED) — Direct Substitute for AHD-IV-LIBRARY
Bottom line
A complete day-by-day IV protocol library was returned, with evidence grades per protocol. This replaces the placeholder AHD-IV-LIBRARY-v0.1 directly as v1.0.
Critical clinical corrections
- Routine IV fluids in AUD are NOT indicated — most patients are euvolemic. Reflexive saline loading worsens hypokalaemic alkalosis. Targeted hydration only.
- Thiamine 500mg IV TDS (3x/day) for 2-3 days is the gold standard, not a single 500mg dose
- Modified rally pack/banana bag thiamine is subtherapeutic as standalone Wernicke prevention; must be paired with high-dose standalone thiamine
- NAD evidence grade is LOW (no RCTs); use as adjunct after acute phase, document Medical Director rationale
- Glutathione evidence is weak (limited NAFLD pilot data only); reserve for cases with elevated LFTs
The IV Library v1.0 (8 protocols)
| # | Protocol | Indication | Evidence |
|---|---|---|---|
| IV-01 | Wernicke Prevention Infusion (thiamine 500mg IV) | All AUD presentations | HIGH |
| IV-02 | Targeted Rehydration + Electrolytes | Clinical dehydration only | HIGH (targeted), LOW (routine) |
| IV-03 | Magnesium Repletion (4g IV) | Hypomagnesaemia in AUD | HIGH |
| IV-04 | Modified Rally Pack | Daily nutritional support Day 2-5 | MEDIUM |
| IV-05 | Glutathione Push (600-1200mg) | Hepatic impairment, elevated LFTs | LOW |
| IV-06 | NAD+ Loading Infusion (250-500mg over 4-6h) | Post-acute Day 4+ | LOW (trials), MEDIUM (safety + mechanism) |
| IV-07 | Methylated B-Complex Push | Day 2+ general | MEDIUM |
| IV-08 | Vitamin C High-Dose (2-5g) | Optional adjunct, high oxidative stress | LOW |
Substance-specific variations confirmed
- Alcohol: thiamine before glucose (non-negotiable), magnesium Day 1, NAD post-acute
- Opioid: hydration for GI losses Day 1, NAD on Day 3-4 once Subutex stabilised
- Benzodiazepine: conservative IV approach; NAD deferred to Day 5+
- Polysubstance: sequenced
Action
- Replace AHD-IV-LIBRARY-v0.1 with v1.0 (full content from Seat 04 brief)
- Update Operating Manual §VIII (IV Protocols) reference
- Update Nursing Curriculum Module 07 with the 8-protocol library
SEAT 05 — UHNW Brand Teardown (LANDED)
Bottom line
Two distinct UHNW brand camps: - Swiss transparency (Paracelsus, Kusnacht) — publish prices, treat publication as confidence gesture - Opacity-as-exclusivity (Knightsbridge, Sollis, Sienna Charles) — never publish, never quote in copy
For AHD: modified opacity is the right model. Publish a price RANGE in the right context (“Engagements typically run between AUD X and AUD Y depending on duration and clinical complexity”) rather than fully opaque or fully transparent.
Voice cues for AHD
- Words to use: investment, engagement, care proposal, clinical scope, duration, proposal, bespoke, discretion, sanctuary, multidisciplinary
- Words to avoid: price, cost, fee, quote, package, programme, exclusive (overused), VIP, package
- Replace “patients” with “principals” or “members”
- Replace “treatment” with “engagement” or “care”
- Replace “facility” with “practice”
Three brand directions for AHD (one to be chosen by Fabian + Kelly)
Direction A: The Physician-Led Firm. Lead with the Medical Director as the credential. Restrained voice. “AVINA is a private medical practice. We provide in-residence clinical care under the direct supervision of a physician. All engagements are led personally by Dr [Name].”
Direction B: The Discretion Architecture Firm. Position the in-residence model as therapeutically superior because it removes the disruption of institutional care. “Recovery conducted outside the principal’s residence introduces variables that in-residence care eliminates.”
Direction C: The Family Office Service Layer. Explicitly target the buyer (FO head, GC, trustee). “AVINA provides family offices and private household advisors with access to immediate, physician-led clinical care in the principal’s residence. Engagements are managed from initial contact to completion without engagement with any institutional health system.”
Power phrases identified
- “without engagement with any institutional health system” — strongest line in the entire teardown; promises no hospital records, no insurance trail, no GP referral
- “we work with one family at a time” — operational exclusivity > aspirational exclusivity
- “an emergency room of one’s own” — Sollis line; AHD analog: “a clinic of one’s own”
Two-sentence test winners
- Version A: “AVINA provides in-residence medical care for individuals who require complete privacy and clinical precision during recovery. Our physicians come to you.”
- Version B: “There is no waiting room. AVINA provides discreet, medically supervised recovery support in the principal’s residence.”
- Version C: “AVINA is a private medical practice providing in-residence detoxification and recovery care. We work with one family at a time.”
Action
- Update Brand Direction v0.1 to v1.0 with the three options spelled out for Fabian + Kelly to choose
- Update marketing site hero copy on avinahomedetox.com draft with chosen direction
- Update Pricing Architecture language: “investment” not “price”; pricing range disclosed in proposal context
CRITICAL DECISIONS FORCED BY THE RESEARCH
Decision A — Nurse Classification (CA)
- Option A1: Employ all CA RNs as W-2 (cost +30-40%, regulatory clean)
- Option A2: Engage only RNs who operate genuine PCs/LLCs with multi-client portfolios (compliance fact-dependent, requires per-RN due diligence)
- Option A3: Hybrid (Director of Nursing employed, supplementary RNs as PC contractors with documented compliance)
- Recommendation: Option A3 for Y1; transition to fully employed model Y2+
Decision B — Capital Plan Revision
- Add HHA licensure (CA + NY + FL): +$30K
- Revise nurse cost basis: ~+$50K Y1 (assuming Option A3 + employment burden)
- Total revised capital ask: $180K vs original $100K — OR same $100K with more aggressive deferral of NY/FL launch to Y2
- Recommendation: Hold $100K cap; defer NY launch to Q1 Y2 and FL to Q2 Y2; CA-only Y1 with full employee model
Decision C — Brand Direction (one of three)
- Recommendation: Direction C (Family Office Service Layer) is the strongest given the buyer journey research. It is the highest-commitment direction but matches the actual purchase pattern.
Decision D — NAD Marketing Claims
- Apply the defensible-claims framework from Seat 1 to all marketing copy
- Train Kelly on the language discipline before any FO mailing
- Counsel review of any public-facing NAD claim before publication
Decision E — Multi-State Strategy
- Original: CA + NY + FL Y1 launch
- Revised: CA only Y1 (HHA + DCFC license + Elizabeth’s CA license + DEA already in place); NY Y2; FL Y2
- This pushes some Y1 revenue right into Y2 but de-risks the regulatory stack massively
REVISED Y1 FINANCIAL PROJECTION (based on the 5 findings)
| Line | Original v0.1 | Revised v1.0 |
|---|---|---|
| Y1 cases | 19 (10 T1 + 9 T2) | 14 (CA-only, slower ramp) |
| Y1 revenue | $581K | $385K |
| Y1 nurse cost | ~$186K @ 32% | ~$165K @ 43% (employee burden) |
| Y1 founders + DON | $186K | $186K (unchanged) |
| Y1 compliance + counsel | $80K | $110K (HHA added) |
| Y1 EBITDA | $79K (14%) | ($45K) — Y1 LOSS |
| Y2 revenue (with NY launch H2) | $2.96M | $2.4M |
| Y2 EBITDA | $886K | $720K |
Implication: With the regulatory and labour findings folded in, Y1 is now a small loss, not a small profit. The $100K capital is consumed. Y2 is still strongly profitable. The model still works, but the Y1 break-even moves from Q3 to Q4 / early Y2.
NEXT ACTIONS (in priority order)
- Update AHD-CAPITAL-PLAN to v1.0 with the revised Y1 cost basis and CA-only Y1 strategy
- Update AHD-REGULATORY-MAP to v1.0 with the verified five-landmine framework
- Update AHD-IV-LIBRARY to v1.0 with the 8 evidence-graded protocols
- Update AHD-BRAND-DIRECTION to v1.0 with three brand directions for Fabian + Kelly to choose
- Update marketing site (site/index.html) with revised NAD claims and chosen brand voice
- Update Counsel Shortlist briefing with the AB5, HHA, controlled-substance, OASAS/DCF, multi-state DEA scope
- Update Operating Hub to reflect LANDED status across all four research-tagged cards
RAW SOURCE BRIEFS
The five raw research briefs are preserved in the task transcripts: - Seat 01 (NAD evidence): /private/tmp/…/tasks/aebfaeac35a72fcbf.output - Seat 02 (Competitive landscape): /private/tmp/…/tasks/a13dce8276fee644a.output - Seat 03 (Regulatory map): /private/tmp/…/tasks/a29d01e13b41cb656.output - Seat 04 (Combined protocol): /private/tmp/…/tasks/a06fbaa4c599e67e1.output - Seat 05 (Brand teardown): /private/tmp/…/tasks/a284f4d31224ac499.output
The briefs total ~25,000 words of evidence-graded research with citations. They are the source of truth for any disputed claim in the synthesis above.
End of v1.0. This synthesis is the input to v0.2 of every foundational document. Counsel review of the regulatory findings is the gating step before any further capital deployment or LLC formation.